ENCITE - European Network for Cell Imaging and Tracking Expertise

Researchers define cell therapy as the transplantation of living cells for the replacement or repair of damaged tissue and/or cells. Hot on the heels of stem cell therapy research is a group of leading cell imaging experts who are participating in ENCITE (European network for cell imaging and tracking expertise), a four-year project supported by the EU with €11 million in funding. Coordinated by the Vienna-based European Institute for Biomedical Imaging Research (EIBIR), ENCITE aims to develop imaging technologies and methods in the cell therapy field.

Experts have established three different principles underlying the treatment of medical disorders: (1) transplanted cells used as an 'active drug'; (2) transplanted cells used to replace damaged and degenerated tissue; and (3) cells used as a drug delivery vehicle.

The medical world has been using cell therapy over the years to treat a myriad of disorders, including cancer, spinal cord injuries, autoimmune disorders and Alzheimer's disease. Contrary to what some people may think, cell therapy is not a new concept; one can trace its history to the German-Swiss physician and alchemist, Phillippus Aureolus Paracelsus, who in 1536 theorised that illnesses can be treated with living tissue.

Fast forward to 2008 and it's clear that the medical world lacks a single imaging modality that would be effective in stem cell therapy. But experts say that several types of imaging have the capacity to play major roles in this line of research, particularly magnetic resonance imaging (MRI) and optical imaging. Both these imaging types are being researched by the ENCITE team.

The partners will develop and test innovative MRI imaging methods and biomarkers so as to better understand what happens to a cell and how the immune system responds. The potential impact of ENCITE is that the researchers will break new ground in cell therapy research, as well as strengthen Europe's role in this type of research. Applications of the results can be seen in the treatment of cancer, diabetes and cardiovascular diseases.

ENCITE kicked off last month and comprises 21 partners from 10 countries. Team members say that as ENCITE advances, the collaboration of other highly qualified partners will prove positive for the project. They add that their contribution will strengthen research or dissemination and training activities for the newly developed methods. ENCITE will launch a Competitive Call in autumn 2008 to secure new partners.

The following actions will be taken by ENCITE in order to meet the call and tackle the different cell therapies that exist: (1) deliver new imaging methods to improve the spatio-temporal tracking of labelled cells; (2) establish dual- and multimodality imaging procedures to cross-validate each individual approach; (3) set up new contrast agents and procedures to enhance the sensitivity and specificity of cellular labelling; and (4) combine molecular biology to produce molecular and cellular imaging reporters with multimodal imaging techniques.

ENCITE states that the application of the targeted imaging tools will contribute to raising awareness of cell therapy, response monitoring in patients and treatment safety.

For further information, please visit:
http://www.eibir.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Johnson & Johnson Announces Submission to Worl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

Sanofi to provide manufacturing support to Johnson…

Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, u...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

Sanofi and GSK initiate new Phase 2 study of their…

Sanofi and GlaxoSmithKline (GSK) announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Ph...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...